Given the potential value of JMJD6 in cancer treatment, researchers have accordingly designed an inhibitor, SKLB325, based on the crystal structure of the jmjC domain of JMJD6, which was demonstrated to possess remarkable antitumor effects in ovarian cancer.33 The gene discussed is JMJD6; the disease is ovarian carcinoma.